Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ex·clu·sivi·ty (n.) – period of uniqueness, typically accompanied by envy and profit

Executive Summary

FDA recognizes data and market exclusivity in its drug approval process, which emanated from laws encouraging the development of drugs for rare diseases and allowing for generic drugs, although the terms themselves do not appear in the bills.

You may also be interested in...



Biosimilars Exclusivity Tug-of-War Brewing In The Mail; Can A Letter Add Eight Years To Reviews?

Rising concerns among generic firms about how FDA will interpret biosimilar exclusivity provisions may have escalated due to fears about the consequences of increased congressional scrutiny of the new pathway.

US FDA User Fee Renewals Remain On Schedule Despite Coronavirus

Virtual kick-off meetings may be necessary, but preparations continue in anticipation of the formal talks to reauthorize the prescription drug, generic drug and biosimilar user fee programs.

Topics

UsernamePublicRestriction

Register

PS053075

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel